Your search history is turned on.
Date: January 30, 2024 Jurisdictions: Alberta, British Columbia
Quest Receives Cash Dividend Payment from OncoQuest Quest Receives Cash Dividend Payment from OncoQuest EDMONTON, AB, Jan. 30, 2024 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received a cash dividend payment...
Date: January 23, 2024 Jurisdictions: Alberta, British Columbia
Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits EDMONTON, AB, Jan. 23, 2024 /CNW/ -...
Date: December 13, 2023 Jurisdictions: Alberta, British Columbia
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Pierre Vermette, Chief Financial Officer of Quest PharmaTech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Quest PharmaTech Inc. (the issuer) for the interim period ended October ...
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Ragupathy (Madi) Madiyalakan, Chief Executive Officer of Quest PharmaTech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Quest PharmaTech Inc. (the issuer) for the interim period...
Quest PharmaTech Inc. Management's Discussion & Analysis For the Nine months ended October 31, 2023 (Expressed in Canadian Dollars, unless otherwise noted) December 13, 2023 Table of Contents Managements Responsibility ................................
Quest PharmaTech Inc. Condensed Interim Consolidated Financial Statements (Unaudited) For the nine months ended October 31, 2023 and 2022 (Expressed in Canadian Dollars, unless otherwise noted) Quest PharmaTech Inc. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS ...
Date: September 21, 2023 Jurisdictions: Alberta, British Columbia
FORM 52-109FV2 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Pierre Vermette, Chief Financial Officer of Quest PharmaTech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Quest PharmaTech Inc. (the issuer) for the interim...
FORM 52-109FV2 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Ragupathy (Madi) Madiyalakan, Chief Executive Officer of Quest PharmaTech Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Quest PharmaTech Inc. (the issue...
Quest PharmaTech Inc. Management's Discussion & Analysis For the Six months ended July 31, 2023 (Expressed in Canadian Dollars, unless otherwise noted) September 21, 2023 Table of Contents Managements Responsibility ...................................
Quest PharmaTech Inc. Condensed Interim Consolidated Financial Statements (Unaudited) For the six months ended July 31, 2023 and 2022 (Expressed in Canadian Dollars, unless otherwise noted) Quest PharmaTech Inc. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For ...